Women wonder
Is our industry really opening doors for women?
King-sized quest
Irrespective of one’s views on institutions and traditions, anyone that does something for 70 years deserves to be saluted.
And, whether you believe in an interventionalist King, it should surely be agreed that a King (with an interest in the environmental issues) should intervene when it comes to climate change – when it comes to an existential crisis.
Pharma remains a massive part of the climate conundrum. Like all other industries, we are simply not doing enough – operating in the margins, setting arbitrary targets of 30% and generally giving ourselves ‘until 2030’ or even 2050! Wildfires, weird heatwaves and rising temperatures suggest that what we’re doing isn’t going to cut it.
Part of the problem is the wider culture of governments convincing us that ‘recycling our Evian bottles’ is the solution. In reality, we need to go bigger – much bigger. Companies need to cut their air travel timetables (the elephant in the room), not by 20%, but by 90%.
Supply chains need to be radically overhauled and people within industry need to be treated with parity regardless of background, identity and ethnicity. After all, health inequalities remain inseparably linked to the environment.
Pharma is a brilliant, unique industry. We saved the world once and we can do it again,
John
Is our industry really opening doors for women?
UK healthcare has been dubbed an institution made by men for men, but the NHS is on the cusp of an integral change
Stem cell transplants have been making headlines and changing lives for 65 years
Brain health vs mental health – redefining how neurological conditions are understood
Oli Hudson grapples with the role of ‘place’ in the new ICS landscape
How the laboratory industry can tackle carbon emissions when developing drugs
Getting closer to the patient – pharma industry reputation in a post-COVID landscape
MAGAZINE EXCLUSIVEElevating the voices of rare disease patients has never been more vital